ProMedica
Brighton, Massachusetts, 02135, United States
NCT Number: NCT01670773
This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy humans.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Brighton, Massachusetts, 02135, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Pre/post each of 3 Single doses
Time frame: Pre/post each of 3 Single doses
Catabasis Pharmaceuticals
Industry
A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.